CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions

Overview of attention for article published in JCO Precision Oncology, December 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 2 news outlets
twitter: 33 X users

bluesky: 1 Bluesky user
podcasts: 1 podcast

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 38 X posts from 33 X users, with an upper bound of 109,209 followers.

RT @TejasPatilMD: 🎉🍾🎗️I'm THRILLED to present the results from CRESTONE (NCT04383210), a multi-center Phase 2 trial of seribantumab in soli…

RT @StephenVLiu: Results from phase II CRESTONE study of seribantumab (HER3 mAb) in NRG1+ tumors @JCOPO_ASCO led by @TejasPatilMD. RR 34.5%…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 34 additional X posts.